Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SNYR 
Synergy CHC Corp. Common Stock (SNYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: SNYR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 147.9% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.24M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 17131 | Beta -1.21 | 52 Weeks Range 0.12 - 10.00 | Updated Date 04/1/2025 |
52 Weeks Range 0.12 - 10.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -50.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.2% | Operating Margin (TTM) 14.75% |
Management Effectiveness
Return on Assets (TTM) 19.91% | Return on Equity (TTM) -361.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 52195130 | Price to Sales(TTM) 0.67 |
Enterprise Value 52195130 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 0.23 | Enterprise Value to EBITDA -0.72 | Shares Outstanding 8703820 | Shares Floating 2379885 |
Shares Outstanding 8703820 | Shares Floating 2379885 | ||
Percent Insiders 72.42 | Percent Institutions 12.27 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Synergy CHC Corp. Common Stock
Company Overview
History and Background
Synergy CHC Corp. was a consumer health company that developed and marketed a range of well-known consumer healthcare brands. It was acquired by Black Diamond Capital Management in 2018 and subsequently delisted. Therefore, it no longer trades as a public company.
Core Business Areas
- Branded Consumer Healthcare Products: Developed, marketed, and distributed over-the-counter (OTC) and personal care products in various consumer healthcare categories.
Leadership and Structure
Prior to its acquisition, Synergy CHC Corp. had a traditional corporate structure with a CEO, CFO, and other executive leadership. Detailed information about the pre-acquisition leadership is publicly accessible via SEC filings prior to its delisting.
Top Products and Market Share
Key Offerings
- ActiPatch: Drug-free pain relief patches for musculoskeletal pain. Market share information prior to the acquisition is difficult to ascertain due to the company being small-cap. Competitors included companies offering similar pain relief products, such as BioWave.
- Fiber Choice: A prebiotic fiber supplement. Again, obtaining accurate market share data is difficult without access to proprietary market research. Competitors included Benefiber (GSK), Metamucil (P&G), and other fiber supplements.
Market Dynamics
Industry Overview
The consumer healthcare industry is characterized by increasing demand for OTC medications and preventative health products, driven by an aging population and increasing healthcare costs. It is a highly competitive market.
Positioning
Prior to its acquisition, Synergy CHC Corp. positioned itself as a developer and marketer of niche consumer health products. Its competitive advantage lay in its portfolio of recognized brands and distribution network.
Total Addressable Market (TAM)
The total addressable market encompasses the global consumer healthcare market, estimated to be in the hundreds of billions of dollars. Synergy CHC Corp., being a smaller player, only addressed a fraction of this market, focusing on specific product categories.
Upturn SWOT Analysis
Strengths
- Established brand portfolio
- Distribution network
- Focus on niche markets
Weaknesses
- Small market capitalization
- Limited financial resources
- Dependence on key brands
Opportunities
- Expanding into new geographic markets
- Developing new products
- Acquiring complementary brands
Threats
- Intense competition
- Changing consumer preferences
- Regulatory changes
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Procter & Gamble (PG)
- Johnson & Johnson (JNJ)
- Bayer (BAYRY)
Competitive Landscape
The consumer healthcare market is highly competitive, with larger players possessing greater resources and brand recognition. Synergy CHC Corp. faced challenges in competing with these established players.
Major Acquisitions
Synergy CHC Corp.
- Year: 2018
- Acquisition Price (USD millions):
- Strategic Rationale: Black Diamond Capital Management acquired Synergy CHC Corp. to restructure and optimize its operations within their portfolio.
Growth Trajectory and Initiatives
Historical Growth: Growth trends prior to the acquisition would reflect the company's success in launching new products and expanding its market presence.
Future Projections: Future projections are no longer applicable since it is not a publicly traded company.
Recent Initiatives: Recent initiatives prior to the acquisition would include new product launches, marketing campaigns, and strategic partnerships.
Summary
Synergy CHC Corp. was a consumer health company with a portfolio of known brands that operated in a competitive landscape. It faced challenges common to small-cap companies in competing with larger, more established players. The company's acquisition by Black Diamond Capital Management suggests that strategic repositioning was deemed necessary. Currently, Synergy CHC Corp. does not exist as a traded common stock.
Similar Companies
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
PG
Procter & Gamble Company
PG
Procter & Gamble Company
Sources and Disclaimers
Data Sources:
- SEC filings prior to acquisition
- Industry reports
- Market research reports
Disclaimers:
The information provided is based on historical data prior to Synergy CHC Corp.'s acquisition and delisting. Market share data is estimated and may not be precise. The company is no longer a publicly traded entity. No present-day data exists for public analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synergy CHC Corp. Common Stock
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 2016-01-04 | CEO & Chairman Mr. Jack Ross | ||
Sector Healthcare | Industry Medical Distribution | Full time employees - | Website https://synergychc.com |
Full time employees - | Website https://synergychc.com | ||
Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products in the United States, Canada, and the United Kingdom. It offers brain health nutritional supplements under the FOCUSfactor brand name; lifestyle and wellness products and accessories, including tea, shakes, lollipops, supplements, apparel, and exercise accessories under the Flat Tummy brand name; products for hands under the Hand MD brand name. The company provides beauty products under the Perfekt Beauty brand; lingerie under Sneaky Vaunt brand; eyelash enhancement products under The Queen Pegasus brand; topical treatments for neuropathic pain under Neuragen brand; and over-the-counter medications under UrgentRx brand. The company sells its products through retailers and television advertising campaigns, as well as skincare products through online. The company was formerly known as Synergy Strips Corp. and changed its name to Synergy CHC Corp. in August 2015. The company was incorporated in 2010 and is based in Westbrook, Maine.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.